CINQAIR®
CINQAIR® (reslizumab) is a treatment for severe, uncontrolled eosinophilic asthma, and for those whose asthma is not controlled with current asthma medicines and who have high levels of eosinophils. CINQAIR is the only anti-IL-5 with personalized weight-based dosing; weight-based dosing enables your doctor to personalize a dose to you.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
